Biotechnology company Laigo Bio has appointed Dr Richard Sainson as Chief Scientific Officer as part of a swathe of board appointments. 

The company, which specialises in autoimmune and inflammatory diseases, says Sainson will lead scientific strategy and oversee the advancement of Laigo’s proprietary SureTACs platform and programmes towards the clinic.  

Sainson has over 25 years of experience in oncology and immunology translational science and drug discovery across academia, global pharma and emerging biotech companies. He has led the scientific strategy for over 15 preclinical programmes and supported the advancement of nine clinical programmes. 

“Richard brings exceptional scientific leadership, deep experience and a strong track record in oncology and immunology,” said Dr Matthew Baker, Chief Executive Officer of Laigo Bio. 

“His appointment as Chief Scientific Officer, together with the addition of our three newly appointed Scientific Advisory Board members, strengthens Laigo’s scientific direction and underscores our commitment to advancing our SureTACs programmes towards the clinic.” 

Elsewhere, Laigo Bio has announced Dr Janine Schuurman, Professor Hans Clevers and Professor David Sansom have all joined the Scientific Advisory Board. 

“Laigo’s ability to attract such highly renowned figures as Richard, Janine, Hans and David to its team and Scientific Advisory Board demonstrates the huge potential of its SureTACs technology platform,” added Dr Neill Moray Mackenzie, Co-Founder and Executive Chairman of Laigo Bio. 

“Their invaluable experience will guide the company’s next phase of growth.” 

The post Laigo Bio announces new CSO as part of board appointments  appeared first on Drug Discovery World (DDW).